ALSO NOTED: Analysts offer conflicting forecasts for Auxilium; test sheds light on cancer therapy; MAP touts new data; and much

> Two analysts assessed Auxilium Pharmaceuticals' chances in a late-stage study of Xiaflex and came up with radically different conclusions. Data is expected in the second quarter. Report [1]

> A new test that analyzes microRNAs can tell doctors the source of some mysterious cancers and help provide a short-cut for treating them, according to media reports quoting researchers in Nature Biotechnology Monday. Report [2]

> MAP Pharma is touting data from a pharmacokinetic trial comparing the systemic drug exposure of UDB compared to the currently marketed conventional nebulized budesonide. Release [3]

> Isolagen has sold its facility in Switzerland for approximately $6.4 million. Release [4]

> Merck and Schering-Plough officials overseeing the Enhance study saw a threat to Vytorin back in late 2005, the Wall Street Journal reports. Report [5]

> Could full clinical trial data disclosure avert scandals? Report [6]

> As Eli Lilly went up to bat in the big Zyprexa trial in Alaska, the judge said lawsuits play a vital role in drug safety. Without them, claims of safety problems "might well go unaddressed," Judge Mark Rindner told the court. Evidence the State of Alaska presented over the past two weeks, he said, shows that the FDA "isn't capable of policing this matter." Report [7]

> The Securities and Exchange Commission charged Biovail, its founder Eugene Melnyk (photo [8]), and three other current and former executives with fraud, alleging that they repeatedly overstated earnings and hid losses. Report [9]

And Finally... A new UN report on tuberculosis control concludes that efforts to rein in the disease have slowed down. Report [10]